BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu K, Min XL, Peng J, Yang K, Yang L, Zhang XM. The Changes of HIF-1α and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma. J Clin Med Res 2016;8:297-302. [PMID: 26985249 DOI: 10.14740/jocmr2496w] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
Number Citing Articles
1 Yang Z, Chen G, Cui Y, Xiao G, Su T, Yu J, Zhang Z, Han Y, Yang K, Jin L. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study. Cancer Biol Ther 2019;20:321-7. [PMID: 30332553 DOI: 10.1080/15384047.2018.1529099] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
2 Marquez HP, Karalli A, Haubenreisser H, Mathew RP, Alkadhi H, Brismar TB, Henzler T, Fischer MA. Computed tomography perfusion imaging for monitoring transarterial chemoembolization of hepatocellular carcinoma. Eur J Radiol 2017;91:160-7. [PMID: 28629564 DOI: 10.1016/j.ejrad.2017.03.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
3 Tzeng WS, Teng WL, Huang PH, Lin TC, Yen FL, Shiue YL. Pterostilbene Nanoparticles Downregulate Hypoxia-Inducible Factors in Hepatoma Cells Under Hypoxic Conditions. Int J Nanomedicine 2021;16:867-79. [PMID: 33574667 DOI: 10.2147/IJN.S282172] [Reference Citation Analysis]
4 Fodor D, Jung I, Turdean S, Satala C, Gurzu S. Angiogenesis of hepatocellular carcinoma: An immunohistochemistry study. World J Hepatol 2019; 11(3): 294-304 [PMID: 30967907 DOI: 10.4254/wjh.v11.i3.294] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
5 Savic LJ, Chapiro J, Geschwind JF. Science to Practice: Killing Dormant Cells-Is Targeting Autophagy the Key to Complete Tumor Response in Transarterial Chemoembolization? Radiology 2017;283:621-3. [PMID: 28514219 DOI: 10.1148/radiol.2017170358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Tak E, Jun DY, Kim SH, Park GC, Lee J, Hwang S, Song GW, Lee SG. Upregulation of P2Y2 nucleotide receptor in human hepatocellular carcinoma cells. J Int Med Res 2016;44:1234-47. [PMID: 27807254 DOI: 10.1177/0300060516662135] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
7 Petrillo M, Patella F, Pesapane F, Suter MB, Ierardi AM, Angileri SA, Floridi C, de Filippo M, Carrafiello G. Hypoxia and tumor angiogenesis in the era of hepatocellular carcinoma transarterial loco-regional treatments. Future Oncology 2018;14:2957-67. [DOI: 10.2217/fon-2017-0739] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
8 Lei HW, Cai J, Li CM, Yang F, Shi WQ, Shi WQ, Wang LP, Feng YY. Rapamycin Combi with TAE on the Growth, Metastasis, and Prognosis of Hepatocellular Carcinoma in Rat Models. Ann Hepatol 2018;17:645-54. [PMID: 29893708 DOI: 10.5604/01.3001.0012.0948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Walter T, Lepage C, Coriat R, Barbier E, Cadiot G, Caroli-Bosc FX, Aparicio T, Bouhier-Leporrier K, Hentic-Dhome O, Gay F, Dupont-Gossart AC, Duluc M, Lepere C, Lecomte T, Smith D, Petorin C, Di-Fiore F, Ghiringhelli F, Legoux JL, Guimbaud R, Baudin E, Lombard-Bohas C, de Baère T; FFCD 1104 investigators/investigators. Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study. Eur J Cancer 2019;123:92-100. [PMID: 31678771 DOI: 10.1016/j.ejca.2019.09.021] [Reference Citation Analysis]
10 Wang D, Zhu H, Cheng W, Lin S, Shao R, Pan H. Effects of hypoxia and ASIC3 on nucleus pulposus cells: From cell behavior to molecular mechanism. Biomedicine & Pharmacotherapy 2019;117:109061. [DOI: 10.1016/j.biopha.2019.109061] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
11 Schobert I, Chapiro J, Pucar D, Saperstein L, Savic LJ. Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors. PET Clinics 2019;14:437-45. [DOI: 10.1016/j.cpet.2019.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Schobert IT, Savic LJ. Current Trends in Non-Invasive Imaging of Interactions in the Liver Tumor Microenvironment Mediated by Tumor Metabolism. Cancers (Basel) 2021;13:3645. [PMID: 34359547 DOI: 10.3390/cancers13153645] [Reference Citation Analysis]
13 Zhang J, Li H, Gao D, Zhang B, Zheng M, Lun M, Wei M, Duan R, Guo M, Hua J, Liu Q, Bai J, Liu H, Zheng J, Yao H. A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE. Cancer Biol Ther. 2018;19:475-483. [PMID: 29400599 DOI: 10.1080/15384047.2018.1433501] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
14 Liu Q, Fan D, Adah D, Wu Z, Liu R, Yan QT, Zhang Y, Du ZY, Wang D, Li Y, Bao SY, Liu LP. CRISPR/Cas9‑mediated hypoxia inducible factor‑1α knockout enhances the antitumor effect of transarterial embolization in hepatocellular carcinoma. Oncol Rep 2018;40:2547-57. [PMID: 30226584 DOI: 10.3892/or.2018.6667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
15 Yang X, Yeung WO, Tan KV, Ng TK, Pang L, Zhou J, Li J, Li C, Li X, Lo CM, Kao WJ, Man K. Development of cisplatin-loaded hydrogels for trans-portal vein chemoembolization in an orthotopic liver cancer mouse model. Drug Deliv 2021;28:520-9. [PMID: 33685316 DOI: 10.1080/10717544.2021.1895908] [Reference Citation Analysis]
16 Schicho A, Pereira PL, Haimerl M, Niessen C, Michalik K, Beyer LP, Stroszczynski C, Wiggermann P. Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy. Oncotarget 2017;8:72613-20. [PMID: 29069813 DOI: 10.18632/oncotarget.19997] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
17 Lin W, Wang H, Zhong M, Yu S, Zhao S, Liang S, Du J, Cheng B, Gu W, Ling C. Effect and Molecular Mechanisms of Jiedu Recipe on Hypoxia-Induced Angiogenesis after Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma. Evid Based Complement Alternat Med 2021;2021:6529376. [PMID: 33505496 DOI: 10.1155/2021/6529376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Fulgenzi CAM, Talbot T, Murray SM, Silletta M, Vincenzi B, Cortellini A, Pinato DJ. Immunotherapy in Hepatocellular Carcinoma. Curr Treat Options Oncol 2021;22:87. [PMID: 34424422 DOI: 10.1007/s11864-021-00886-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Covey AM, Hussain SM. Liver-Directed Therapy for Hepatocellular Carcinoma: An Overview of Techniques, Outcomes, and Posttreatment Imaging Findings. American Journal of Roentgenology 2017;209:67-76. [DOI: 10.2214/ajr.17.17799] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
20 Fan SKY, Li B, Chen Q, Midia M. Impact of Interventional Oncology Therapies on Tumor Microenvironment and Strategies to Enhance Their Efficacy. AJR Am J Roentgenol 2018;210:648-56. [PMID: 29364726 DOI: 10.2214/AJR.16.17677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Dong G, Lin XH, Liu HH, Gao DM, Cui JF, Ren ZG, Chen RX. Intermittent hypoxia alleviates increased VEGF and pro-angiogenic potential in liver cancer cells. Oncol Lett 2019;18:1831-9. [PMID: 31423251 DOI: 10.3892/ol.2019.10486] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
22 Abdelaziz AO, Abdelhalim H, Elsharkawy A, Shousha HI, Abdelmaksoud AH, Soliman ZA, Seif MI, Sayed DB, Farouk MH, Elbaz TM, Nabeel MM. Liver stiffness measurement changes following hepatocellular carcinoma treatment with percutaneous microwave ablation or transarterial chemoembolization: a cohort study. Eur J Gastroenterol Hepatol 2019;31:685-91. [PMID: 30640743 DOI: 10.1097/MEG.0000000000001343] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Fako V, Martin SP, Pomyen Y, Budhu A, Chaisaingmongkol J, Franck S, Lee JM, Ng IO, Cheung TT, Wei X, Liu N, Ji J, Zhao L, Liu Z, Jia HL, Tang ZY, Qin LX, Kloeckner R, Marquardt J, Greten T, Wang XW. Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization. Int J Biol Sci 2019;15:2654-63. [PMID: 31754337 DOI: 10.7150/ijbs.39534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
24 Xu X, Tao Y, Shan L, Chen R, Jiang H, Qian Z, Cai F, Ma L, Yu Y. The Role of MicroRNAs in Hepatocellular Carcinoma. J Cancer 2018;9:3557-69. [PMID: 30310513 DOI: 10.7150/jca.26350] [Cited by in Crossref: 57] [Cited by in F6Publishing: 64] [Article Influence: 19.0] [Reference Citation Analysis]
25 Arora S, Catania R, Borhani A, Horvat N, Fowler K, Harmath C. HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy. Abdom Radiol (NY) 2021;46:3686-97. [PMID: 34195886 DOI: 10.1007/s00261-021-03192-8] [Reference Citation Analysis]
26 Han Y, Cao G, Sun B, Wang J, Yan D, Xu H, Shi Q, Liu Z, Zhi W, Xu L, Liu B, Zou Y. Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study. BMC Gastroenterol 2021;21:393. [PMID: 34670512 DOI: 10.1186/s12876-021-01967-3] [Reference Citation Analysis]
27 Farid K, Elalfy H, Abo El-Khair SM, Elgamal H, Besheer T, Elmokadem A, Shabana W, Abed S, Elegezy M, El-Khalek AA, El-Morsy A, Negm A, Elsamanoudy AZ, El Deek B, Amer T, El-Bendary M. Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients. Expert Rev Gastroenterol Hepatol 2020;14:1203-14. [PMID: 32933325 DOI: 10.1080/17474124.2020.1823215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
28 Sutphin PD, Lamus D, Kalva SP, Li J, Corbin IR. Interventional Radiologic Therapies for Hepatocellular Carcinoma: From Where We Began to Where We Are Going. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 169-94. [DOI: 10.1007/978-3-030-21540-8_9] [Reference Citation Analysis]
29 Ni JY, Xu LF, Wang WD, Huang QS, Sun HL, Chen YT. Transarterial embolization combined with RNA interference targeting hypoxia-inducible factor-1α for hepatocellular carcinoma: a preliminary study of rat model. J Cancer Res Clin Oncol 2017;143:199-207. [PMID: 27638772 DOI: 10.1007/s00432-016-2237-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
30 Guo W, Chen S, Wu Z, Zhuang W, Yang J. Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study. Technol Cancer Res Treat 2020;19:1533033820965587. [PMID: 33089769 DOI: 10.1177/1533033820965587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Mao J, Tan Z, Pan X, Meng F. ASPP2 expression predicts the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. Exp Ther Med 2021;21:397. [PMID: 33680119 DOI: 10.3892/etm.2021.9828] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Nahm JH, Rhee H, Kim H, Yoo JE, San Lee J, Jeon Y, Choi GH, Park YN. Increased expression of stemness markers and altered tumor stroma in hepatocellular carcinoma under TACE-induced hypoxia: A biopsy and resection matched study. Oncotarget. 2017;8:99359-99371. [PMID: 29245907 DOI: 10.18632/oncotarget.22078] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]